-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6436 in Enterobacteriaceae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6436 in Enterobacteriaceae Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6436 in Enterobacteriaceae Infections Drug Details: RG-6436 (GDC-0829) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6631 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6631 in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6631 in Autoimmune Disorders Drug Details: RG-6631 (RVT-3101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-7827 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-7827 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-7827 in Solid Tumor Drug Details: RG-7827 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6436 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6436 in Urinary Tract Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6436 in Urinary Tract Infections Drug Details: RG-6436 (GDC-0829) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6436 in Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6436 in Pseudomonas aeruginosa Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6436 in Pseudomonas aeruginosa Infections Drug Details: RG-6436 (GDC-0829) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-7827 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-7827 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-7827 in Metastatic Colorectal Cancer Drug Details: RG-7827 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-7827 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-7827 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-7827 in Non-Small Cell Lung Cancer Drug Details: RG-7827...
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s RG-6237
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6237 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s RG-6341
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6341 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.